Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | RXRB | P28702 | 1/20 | 0.51 |
| ▸ | RXRG | P48443 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | PGR | P06401 | 3/20 | 0.45 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.45 |
| ▸ | FABP3 | P05413 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13523299 | 0.88 | TAAR1 (0.55) | RXRARXRBRXRGESR2ALOX5 | |
| SCHEMBL254476 | 0.87 | PGR (0.47) | PGRPNMTKDM4EMDM4ALDH1A1 | |
| SCHEMBL29428797 | 0.87 | PGR (0.47) | PGRPNMTKDM4EMDM4ALDH1A1 | |
| SCHEMBL5352034 | 0.87 | RXRA (0.62) | RXRARXRBRXRGPTPN5KDM4E | |
| SCHEMBL13118526 | 0.86 | RXRA (0.59) | RXRARXRBRXRGALOX5TAAR1 | |
| Ammonia Solution, Strong SCHEMBL16197665 | 0.85 | PGR (0.46) | PGRPNMTKDM4EMDM4ALDH1A1 | |
| SCHEMBL598181 | 0.84 | RXRA (0.66) | RXRARXRBRXRGPTPN5CYP2C9 | |
| SCHEMBL29727265 | 0.83 | RXRA (0.65) | RXRARXRBRXRGPTPN5CYP2C9 | |
| SCHEMBL5355878 | 0.83 | RXRA (0.65) | RXRARXRBRXRGPTPN5CYP2C9 | |
| Ethane SCHEMBL6908245 | 0.82 | RXRA (0.63) | RXRARXRBRXRGPTPN5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2016-08-11 | — | — | US | disclosed |
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-7807672-B2 | Compounds that are ERK inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| WO-2003084931-A1 | 5H-BENZO[4,5]CYCLOHEPTA[1,2-B]PYRIDINE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | BACE1, STS, APP | RXRA 4297/4885RXRB 3838/4885RXRG 4359/4885 |
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | BACE1, BACE2, PSEN2 | RXRA 2457/4885RXRB 1603/4885RXRG 1865/4885 |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | RXRA 3626/4885RXRB 2976/4885RXRG 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.